newsfilter
← Latest News
GlobeNewswire·

Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Following FDA consultation, announced plans for validation of the Gen-2 Optejet® device and 2025 regulatory submission with Mydcombi™ as lead product Advanced Phase 3 CHAPERONE study of MicroPine as a